PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group ( median 34 months [ 95 % CI 29-39 ] vs 27 months [ 26-28 ] ; hazard ratio [ HR ] 079 [ 95 % CI 068-092 ] , p = 00019 ) .